Manali Kamdar
About
Manali Kamdar is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics.
According to data from OpenAlex, Manali Kamdar has authored 90 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Oncology, 53 papers in Pathology and Forensic Medicine and 26 papers in Genetics. Recurrent topics in Manali Kamdar's work include Lymphoma Diagnosis and Treatment (53 papers), CAR-T cell therapy research (43 papers) and Chronic Lymphocytic Leukemia Research (25 papers). Manali Kamdar is often cited by papers focused on Lymphoma Diagnosis and Treatment (53 papers), CAR-T cell therapy research (43 papers) and Chronic Lymphocytic Leukemia Research (25 papers). Manali Kamdar collaborates with scholars based in United States, Switzerland and Canada. Manali Kamdar's co-authors include Tae Min Kim, Won Seog Kim, Alex F. Herrera, Laurie H. Sehn, Matthew J. Matasar, Christopher R. Flowers, Ji Cheng, Muhıt Özcan, Andrew McMillan and Grace Ku and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.
In The Last Decade
Manali Kamdar
73 papers receiving 1.3k citations
Hit Papers
Peers
Manali Kamdar
Amitkumar Mehta United States
Jeff Wiezorek United States
Matthew Ku Australia
Connie Lee Batlevi United States
David Belada Czechia
Anne Beaven United States
Juan Pablo Alderuccio United States
Cinzia Pellegrini Italy
Zhitao Ying China
Citations per year, relative to Manali Kamdar Manali Kamdar (= 1×)
peers
Amitkumar Mehta
Countries citing papers authored by Manali Kamdar
Since
Specialization
Citations
This map shows the geographic impact of Manali Kamdar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manali Kamdar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manali Kamdar more than expected).
Fields of papers citing papers by Manali Kamdar
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Manali Kamdar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manali Kamdar. The network helps show where Manali Kamdar may publish in the future.
Co-authorship network of co-authors of Manali Kamdar
This figure shows the co-authorship network connecting the top 25 collaborators of Manali Kamdar. A scholar is included among the top collaborators of Manali Kamdar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manali Kamdar. Manali Kamdar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Kamdar, Manali, Sairah Ahmed, Jeremy S. Abramson, et al.. (2025). CT-305: Optimizing Post-Chimeric Antigen Receptor (CAR) T-Cell Monitoring: Evidence Across Lisocabtagene Maraleucel (liso-cel) Pivotal Clinical Trials and Real-World Experience. Clinical Lymphoma Myeloma & Leukemia. 25. S1010–S1011.
2.
Hunter, Bradley D., Matthew A. Lunning, Sairah Ahmed, et al.. (2025). CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting. Transplantation and Cellular Therapy. 32(2). 171.e1–171.e12.
3.
Strati, Paolo, Januario E. Castro, Aaron M. Goodman, et al.. (2025). Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory B-cell lymphoma: a multicentre, open-label, phase 1 study. The Lancet Haematology. 12(7). e505–e515.
4.
Desai, Pinkal, Sagar Lonial, Amanda F. Cashen, et al.. (2024). A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies. Clinical Cancer Research. 30(21). 4844–4855.
5.
Assouline, Sarit, Lihua E. Budde, Julio C. Chávez, et al.. (2024). Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL).. Journal of Clinical Oncology. 42(16_suppl). 7021–7021.
6.
Assouline, Sarit, Lihua E. Budde, Julio C. Chávez, et al.. (2024). Mosunetuzumab With Polatuzumab Vedotin: Subgroup Analyses in Patients (pts) With Primary Refractory or Early Relapsed Large B-Cell Lymphoma (LBCL). Clinical Lymphoma Myeloma & Leukemia. 24. S212–S212.
7.
Abramson, Jeremy S., Scott R. Solomon, Jon Arnason, et al.. (2024). Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen. Future Oncology. 20(21). 1455–1465.
8.
Kamdar, Manali, Scott R. Solomon, Jon Arnason, et al.. (2024). Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study.. Journal of Clinical Oncology. 42(16_suppl). 7013–7013.
9.
Abramson, Jeremy S., Manali Kamdar, Alessandro Crotta, et al.. (2024). Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Second-Line (2L) Treatment of Patients (pts) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL): Update with 34 Months of Liso-Cel Follow-up. Blood. 144(Supplement 1). 3130–3130.
10.
Nastoupil, Loretta J., Manali Kamdar, Julio C. Chávez, et al.. (2023). LISOCABTAGENE MARALEUCEL (LISO‐CEL) VERSUS STANDARD OF CARE (SOC) AS SECOND‐LINE THERAPY IN LARGE B‐CELL LYMPHOMA (TRANSFORM STUDY): SUBGROUP ANALYSES BY PRIOR THERAPY RESPONSE. Hematological Oncology. 41(S2). 212–214.
11.
Haverkos, Bradley M., Jasmine M. Zain, Manali Kamdar, et al.. (2023). Frontline chemoimmunotherapy with nivolumab and dose-adjusted EPOCH in peripheral T-cell lymphoma: a phase 1 trial. Blood Advances. 8(3). 708–711.
12.
Colton, Meryl D., et al.. (2023). A CASE SERIES OF PATIENTS WITH CUTANEOUS T‐CELL LYMPHOMA TREATED WITH COMBINATION MOGAMULIZUMAB AND OTHER THERAPIES AFTER SINGLE AGENT MOGAMULIZUMAB. Hematological Oncology. 41(S2). 772–774.
13.
Abramson, Jeremy S., Scott R. Solomon, Jon Arnason, et al.. (2022). Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor T Cell Therapy, Compared with Standard of Care (SOC) Using Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study. Transplantation and Cellular Therapy. 28(3). S188–S189.
14.
Solomon, Scott R., Amitkumar Mehta, Jeremy S. Abramson, et al.. (2021). Experience of Prior Anti-CD19 Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Non-Hodgkin Lymphoma (B-NHL) Receiving Lisocabtagene Maraleucel (liso-cel), an Investigational Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Product. Transplantation and Cellular Therapy. 27(3). S207–S208.
15.
Amaya, Maria L., Antonio Jimeno, & Manali Kamdar. (2020). Polatuzumab vedotin to treat relapsed or refractory diffuse largeB-cell lymphoma, in combination with bendamustine plus rituximab. Drugs of today. 56(4). 287–287.
16.
Kamdar, Manali, Hongli Li, Robert W. Chen, et al.. (2019). Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. Blood Advances. 3(20). 3132–3135.
17.
Jaglowski, Samantha, Zhen‐Huan Hu, Yiyun Zhang, et al.. (2019). Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry. Blood. 134(Supplement_1). 766–766.
18.
Pollyea, Daniel A., Clayton A. Smith, Enkhtsetseg Purev, et al.. (2018). Thiotepa-Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared with Transplantation Following Standard Reduced-Intensity Conditioning: A Retrospective Cohort Comparison. Biology of Blood and Marrow Transplantation. 24(8). 1671–1677.
19.
Smith, Derek, et al.. (2018). Addition of Rituximab to High-Dose Methotrexate Regimens Improves Complete Response Rates and Median Overall Survival in Non-Germinal Center Primary CNS Lymphoma. Blood. 132(Supplement 1). 4217–4217.
20.
Sehn, Laurie H., Alex F. Herrera, Matthew J. Matasar, et al.. (2017). Addition of Polatuzumab Vedotin to Bendamustine and Rituximab (BR) Improves Outcomes in Transplant-Ineligible Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Versus BR Alone: Results from a Randomized Phase 2 Study. Blood. 130. 2821–2821.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Amitkumar Mehta Breakdown of academic impact, for papers by Jeff Wiezorek Breakdown of academic impact, for papers by Matthew Ku Breakdown of academic impact, for papers by Connie Lee Batlevi Breakdown of academic impact, for papers by David Belada Breakdown of academic impact, for papers by Anne Beaven Breakdown of academic impact, for papers by Juan Pablo Alderuccio Breakdown of academic impact, for papers by Cinzia Pellegrini Breakdown of academic impact, for papers by Zhitao Ying